Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00426-1/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=280173067&_hsenc=p2ANqtz-9-hRHhBdYXhKNUyxOf5o6h38-bj6Fd-YpxmaSksfY78PCFypG8ARsi9YNq4DAWdtS-V4rasynUURJUcSZgR86Sb8dDQA&utm_content=280145645&utm_source=hs_email